CT/MRI Co-registration Prostate Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00252460 |
|
Recruitment Status
:
Completed
First Posted
: November 11, 2005
Last Update Posted
: March 25, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The target volume in prostate cancer radiotherapy typically consists of the entire prostate gland which is localized by contours drawn on axial computed tomography (CT) radiation planning images. Compared with CT, magnetic resonance (MR) can provide better definition of the prostate gland with respect to the surrounding tissues and the use of multi-plannar reconstruction avoids the problem of partial volume averaging inherent in CT. CT has been shown to significantly overestimate the volume of the gland using the MR-defined prostate volume as the gold standard. Co-registration of MR and CT datasets, matched on fixed bony landmarks, has enabled radiation planning using a MR-defined clinical target volumes, combined with CT-based electron density information necessary for radiation treatment planning.
Rationale and Hypothesis:
Co-registration may allow better delineation of tumour volumes in prostate cancer. This investigation is a fesibility study designed to evaluate and optimize imaging parameters and co-registration techniques for CT planning and MRI Simulator.
| Condition or disease | Intervention/treatment |
|---|---|
| Prostatic Neoplasm | Device: Computed Tomography Scan and Magnetic Resonance Imaging |
| Study Type : | Observational |
| Actual Enrollment : | 31 participants |
| Time Perspective: | Prospective |
| Official Title: | Evaluation of Planning Computed Tomography Scan and Magnetic Resonance Imaging Simulator Scan Co-Registration for Delineation of Gross Tumour Volume in Radiotherapy Treatment of Localized Prostate Cancer |
| Study Start Date : | November 2003 |
| Actual Primary Completion Date : | November 2010 |
| Actual Study Completion Date : | November 2010 |
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Histological confirmation of Prostate Adenocarcinoma
- Undergoing RT with fiducial markers, IMRT or Escalated Dose Conformal RT
Exclusion Criteria:
- Contraindication for MRI
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00252460
| Canada, Ontario | |
| University Health Network | |
| Toronto, Ontario, Canada, M5G 2M9 | |
| Principal Investigator: | Andrew Bayley, MD | Princess Margaret Hospital, Canada |
| Responsible Party: | University Health Network, Toronto |
| ClinicalTrials.gov Identifier: | NCT00252460 History of Changes |
| Other Study ID Numbers: |
UHN REB 03-0601-CE |
| First Posted: | November 11, 2005 Key Record Dates |
| Last Update Posted: | March 25, 2016 |
| Last Verified: | March 2016 |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site |
Neoplasms Genital Diseases, Male Prostatic Diseases |